Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?
Summary: Tirzepatide (dual GIP/GLP-1) generally produces greater average weight loss (~20-22% vs ~15%) but both are effective. Semaglutide has a longer track record and wider provider availability. Cost varies by provider.
Side-by-Side Comparison
| Category | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Brands | Wegovy, Ozempic, Rybelsus | Zepbound, Mounjaro |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA Approval (weight loss) | 2021 (Wegovy) | 2023 (Zepbound) |
| Avg weight loss (clinical trials) | ~15% over 68 weeks | ~20-22% over 72 weeks |
| Injection frequency | Once weekly | Once weekly |
| Starting dose | 0.25mg | 2.5mg |
| Max dose | 2.4mg (Wegovy) | 15mg (Zepbound) |
| Compounded versions available | Yes | Yes |
This comparison is for informational purposes only and does not constitute medical advice. Consult a healthcare provider for personalized guidance.